RecruitingNot ApplicableNCT02993029

99Tc-MDP Treatment for Knee Osteoarthritis

99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Enrollment

40 participants

Start Date

Sep 1, 2017

Study Type

INTERVENTIONAL

Conditions

Treatment Outcome

Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

Eligibility

Min Age: 40 Years

Inclusion Criteria3

Participants with painful osteoarthritis;
The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;
Participants voluntarily participate in the trial, and signed the informed consent.

Exclusion Criteria6

Knee joint replacement;
Inflammatory arthritis or joint infection of knee;
Nervous joint disease;
Fracture of joint;
Gout arthritis of the knee;
Traumatic arthritis.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG99Tc-MDP

99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.

DRUGCelecoxib

Celecoxib capsule 200mg qd by mouth.